Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Yishai OfranRonit LeibaAvraham FrischNurit HoreshIsrael HenigDana Yehudai-OfirYakir MosheMiriam NeamanChezi GanzelKinneret Gal-RabinovichIlana HellmannVladimir WeinsteinTamar BergerOfir WolachPublished in: European journal of haematology (2020)
Our results demonstrate benefits of midostaurin incorporation in intensive chemotherapy regimens, particularly for high-AR AML patients to whom it should be offered along with allo-SCT in CR1.
Keyphrases
- acute myeloid leukemia
- stem cell transplantation
- high dose
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- locally advanced
- prognostic factors
- systemic lupus erythematosus
- squamous cell carcinoma
- low dose
- tyrosine kinase
- disease activity
- acute lymphoblastic leukemia
- chemotherapy induced
- patient reported